Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 5 Results

Title
Intervention Indication Therapeutic Area Year Actions
Avelumab with or without Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer – second line Avelumab (Bavencio; MSB-0010718C) , Pegylated liposomal doxorubicin Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Avelumab in combination with axitinib for advanced or metastatic renal cell carcinoma – first line Avelumab (Bavencio; MSB-0010718C) , Axitinib (Inlyta; AG-013736) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer Avelumab (Bavencio; MSB-0010718C) Bladder cancer Urological Cancer 2019 View  |  Download
Avelumab for gastric or gastro-oesophageal junction cancer - first line maintenance Avelumab (Bavencio; MSB-0010718C) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Avelumab for gastric and gastroesophageal junction adenocarcinoma – third line Avelumab (Bavencio; MSB-0010718C) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications